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Abstract
Background: Cancer-related self-tests are currently available to buy in pharmacies or over the
internet, including tests for faecal occult blood, PSA and haematuria. Self-tests have potential
benefits (e.g. convenience) but there are also potential harms (e.g. delays in seeking treatment). The
extent of cancer-related self-test use in the UK is not known. This study aimed to determine the
prevalence of cancer-related self-test use.
Methods: Adults (n = 5,545) in the West Midlands were sent a questionnaire that collected socio-
demographic information and data regarding previous and potential future use of 18 different self-
tests. Prevalence rates were directly standardised to the England population. The postcode based
Index of Multiple Deprivation 2004 was used as a proxy measure of deprivation.
Results: 2,925 (54%) usable questionnaires were returned. 1.2% (95% CI 0.83% to 1.66%) of
responders reported having used a cancer related self test kit and a further 36% reported that they
would consider using one in the future. Logistic regression analyses suggest that increasing age,
deprivation category and employment status were associated with cancer-related self-test kit use.
Conclusion: We conclude that one in 100 of the adult population have used a cancer-related self-
test kit and over a third would consider using one in the future. Self-test kit use could alter
perceptions of risk, cause psychological morbidity and impact on the demand for healthcare.
Background
Self-tests enable an individual to check for signs of certain
health conditions without recourse to a health profes-
sional by getting a result immediately e.g. most prostate
specific antigen (PSA) and faecal occult blood (FOB) tests,
or by sending a sample to a laboratory that returns the
result directly to the individual e.g. some chlamydia tests.
Such tests can be diagnostic e.g. urine tests for pregnancy,
for disease monitoring e.g. blood pressure, or both e.g.
PSA tests. Self-tests related to the diagnosis of more than
20 different conditions are available to the UK public via
the internet [1].
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Several reports have expressed concern about the develop-
ment of self-testing [2-4]. Potential problems highlighted
include: lack of professional support when receiving bad
news; lack of expertise to interpret or act on results; unre-
liable results generating false security or anxiety; that indi-
viduals may be forced to take tests by people other than
health professionals (e.g. employers); the breakdown of
public health surveillance; and that commercially driven
test development may lead to demands which the NHS is
unable to meet for further testing or treatment. Much of
the coverage of self-testing in the press is also negative,
warning of the unreliability of tests and the dangers of
misunderstanding medical information [5-7].
Despite this, in 2003, market researchers reported that
"almost six in ten Britons diagnose themselves at home
with self-testing equipment instead of going to the doc-
tor" [8], although this figure does include thermometers
as a self-test device. Sales of self-testing equipment are
reported to have increased dramatically: almost 54.3 m
was spent on self-diagnostic products in 2002, a 32%
growth since 1998 [9], and it was predicted that would
rise to over £60 m by 2007 [8]. Long waits to see a GP and
an increasingly health-conscious population are among
the factors thought to contribute to the increased sales
[10]. Other possible reasons include privacy and conven-
ience.
In the UK, NHS Direct and drop-in health centres aim to
increase access to health services and health information
[11]. Such initiatives, together with interventions aiming
to redefine patients as consumers e.g. Patient Advice and
Liaison Services, the increased availability of over the
counter medication and funding pressures on health serv-
ice providers, have encouraged the development of a self-
care culture with people taking more responsibility for
their own health [12-14]. Self testing may be considered
to be a potentially important part of self care within con-
ventional medicine, for example empowering people
within a consultation with their doctor, as has been seen
with the use of internet resources [15]. Conversely though
self-tests may be used by those not wishing to bother doc-
tors, perhaps appealing to those who are dissatisfied with
or mistrustful of doctors or conventional medicine.
Health Which [7], the press [5,6] and cancer support
groups [16] have reported the availability of cancer self-
test kits from high street chemists. Cancer-related self-tests
that are currently available in UK pharmacies and over the
internet include those for faecal occult blood, PSA and
haematuria [1]. Should Internet sales be shown to be prof-
itable, a wider range of cancer self-test kits is likely to
become available from pharmacies. Saliva tests for breast
cancer risk [17] and kits for testing the response to alter-
native cancer treatments [18] are already being marketed
via the internet. Other potential new developments
include a saliva test for breast cancer [19], bladder cancer
home tests (currently prescription only) [20], and tests
related to genetic determinants of cancer [21] and drug
effectiveness [22].
Despite this, little is known about the extent to which peo-
ple screen themselves for cancer or their reasons: there are
no studies that have determined the extent of cancer-
related self-test use in the UK. The limited literature that
does address self-testing has also tended to concentrate on
efficacy and reliability [23,24], has been carried out in dif-
ferent health cultures in the US or Europe [25], or is based
on opinion only without empirical data [26]. Self-tests for
cancer could alter perceptions of risk and health behav-
iour, cause psychological morbidity and have a significant
impact on the demand for healthcare. Furthermore, they
may impact on the cost-effectiveness of population-based
screening. It is essential, therefore, that we gain an under-
standing of the frequency of self-testing for cancer, charac-
teristics of users, and the impact on users and the health
service. This study aimed to determine the prevalence of
cancer-related self-test use.
Methods
The methods used are described more fully elsewhere
[27]. Following ethical and RM&G approval (Solihull
LREC, 22nd March 2005, Ref: 05/Q2706/13, Birmingham
and Solihull PCT Research Management and Governance
Approval, 29/06/05, Project No: 754), four general prac-
tices in Birmingham were recruited. Postal questionnaires
and prepaid envelopes were sent to 5,545 people aged
over 18 and registered with the participating practices.
People that the GP deemed inappropriate to approach, for
example because of recent bereavement, were excluded.
A covering letter briefly defined 'self-testing' as "a test or
kit bought from a shop or over the internet that is used to
see if you have a condition or disease without involving a
doctor or a nurse", explained the study and requested that
a blank form be returned if they did not wish to partici-
pate. The three-page questionnaire collected socio-demo-
graphic information and data regarding previous and
potential future use of self-test kits. The questionnaire was
piloted to ensure readability, comprehension, and accept-
ability. To minimise response bias, questions concerned
self-testing for a range of conditions, rather than just can-
cer, were included. Respondents were asked whether they
had used a self test for 18 different conditions (including
diabetes, cholesterol, cystitis, prostate cancer, bowel can-
cer and haematuria) or would use such tests in the future
(Yes, No, Don't Know response categories). Non-respond-
ers received one reminder.BMC Cancer 2008, 8:102 http://www.biomedcentral.com/1471-2407/8/102
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Data analysis was undertaken using SPSS version 12 and
Mintab. Analyses aimed to scope the extent and patterns
of current cancer-related self-test use and produce profiles
of the people who had used or would use self-testing for
cancer. Participants were classified according to their use
of self-test kits related to cancer (yes, no). Categorical
analyses compared those reporting using self-tests with all
other categories (no, don't know and blank).
Participation comprised the completion of a three page
postal questionnaire. We kept questionnaire length to a
minimum to maximise compliance and minimise selec-
tion bias.
Prevalence rates were directly standardised, by age, sex
and deprivation, to the England population. The Index of
Multiple Deprivation 2004 (IMD 2004) [28] was used as
a proxy measure of multiple deprivation based on the
respondent's postcode of residence. This model of multi-
ple deprivation is based on the idea of distinct dimensions
of deprivation (employment, health deprivation and dis-
ability, education skills and training, barriers to housing
and services, crime and living environment), experienced
by individuals living in an area, which can be recognized
and measured separately. The IMD score is a weighted
area level aggregation of these dimensions of deprivation.
Lower IMD scores indicate less deprived areas of resi-
dence. Ranked data were converted to quartiles for analy-
sis; quartile 1 representing the most affluent group and
quartile 4 the most deprived [28].
Logistic regression was used to establish a set of character-
istics which jointly distinguish those who had used a self
test kit from those who had not done so. The same tech-
nique was used to distinguish those who believed that
they may make use of a particular self test kit in the future
from those who did not think that they would do so.
Results
Three hundred and ninety three patients were excluded
from practice lists because their GPs felt it was inappropri-
ate to send them a questionnaire. The reasons for exclu-
sion were given as: 101 because of severe or terminal
illness (including mental illness), 9 because they were
practice staff, 170 because they were too frail, and 113 for
other reasons. Five thousand five hundred and forty five
questionnaires were mailed, but 133 were returned as
"address unknown", giving a denominator of 5,412 (Fig-
ure 1). Completed questionnaires were returned by 2,925
patients and 207 were returned blank (response rate 58%,
usable responses 54%).
The mean age of responders was 53 years (range 18 to 95);
45% (n = 1,308 of 2,925) were male; 92% (n = 2,698)
were white; 20% (n = 578) were smokers; 88% (n =
2,580) reported their health to be good or fairly good;
51% (n = 1,495) were in paid employment and 33% (n =
Study schematic Figure 1
Study schematic.
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970) retired; and 19% (n = 551) had a university degree
(Table 1). Responders were more likely to be female (χ2 =
76.1, P < 0.0001), older (χ2 = 354.49 (2 DF), P < 0.0001)
and from more affluent areas (χ2 = 121.08 (3 DF), P <
0.0001).
Table 1: Baseline characteristics of participants
Characteristics All (n = 2,925) Cancer self-test users (n = 35) Test*
Age, years
Mean (range) 53.1 (18–95) 58.8 (30–87) t=-1.92, 2923df
Median 53 60 p = 0.055
GenderN  ( % ) N  ( % )
Male 1308 (44.7) 21 (60.0) χ2 = 3.35,1df
Female 1617 (55.3) 14 (40.0) p = 0.067
Index of Multiple Deprivation (n = 2,922) N (%) N (%)
Quartile 1 (least deprived) 433 (14.8) 4 (11.4) χ2 = 0.35,3df
Quartile 2 566 (19.4) 7 (20.0) p = 0.951
Quartile 3 1230 (42.1) 15 (42.9)
Quartile 4 (most deprived) 693 (23.7) 9 (25.7)
Smoking Status N (%) N (%)
Smoker 578 (19.8) 5 (14.3) χ2 = 0.85,2df
Non-smoker 2334 (79.8) 30 (85.7) p = 0.654
Not known 13 (0.4) 0 (0.0)
Ethnic Group N (%) N (%)
White 2698 (92.2) 31 (88.6) χ2 = 3.71,5df
Mixed 25 (0.9) 0 (0.0) p = 0.592
Asian 99 (3.4) 1 (2.9)
Black 35 (1.2) 1 (2.9)
Chinese 9 (0.3) 0 (0.0)
Other & Not known 59 (2.0) 2 (5.7)
Exercise Regularly N (%) N (%)
Yes 1380 (47.2) 16 (45.7) χ2 = 0.03,2df
No 1466 (50.1) 18 (51.4) p = 0.984
Not known 79 (2.7) 1 (2.9)
Health Status N (%) N (%)
Not good 324 (11.1) 5 (14.3) χ2 = 2.92,3df
Fairly good 1220 (41.7) 15 (42.9) p = 0.404
Good 1360 (46.5) 14 (40.0)
Not known 21 (0.7) 1 (2.9)
Long Term Illness N (%) N (%)
Yes 811 (27.7) 12 (34.3) χ2 = 0.76,2df
No 2020 (69.1) 22 (62.9) p = 0.684
Not known 94 (3.2) 1 (2.9)
Education (highest level) N (%) N (%)
Degree 551 (18.8) 5 (14.3) χ2 = 4.50,5df
Further qualifications 1056 (36.1) 15 (42.9) p = 0.480
Left school some qualifications 491 (16.8) 4 (11.4)
Left school no qualifications 718 (24.5) 10 (28.6)
Did not go to school 24 (0.8) 1 (2.9)
Other & Not known 85 (2.9) 0 (0.0)
Employment N (%) N (%)
In paid employment 1291 (44.1) 11 (31.4) χ2 = 8.00,7df
Self-employed/freelance 204 (7.0) 3 (8.6) p = 0.333
Unemployed 90 (3.1) 0 (0.0)
Retired 970 (33.2) 16 (45.7)
Student 63 (2.2) 0 (0.0)
Looking after home/family 157 (5.4) 4 (11.4)
Sick/disabled 103 (3.5) 1 (2.9)
Other 47 (0.6) 0 (0.0)
*Comparisons relate to cancer self-test users versus all others (i.e. non-cancer self test users and non-self test users)BMC Cancer 2008, 8:102 http://www.biomedcentral.com/1471-2407/8/102
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Almost a third of the responders (969 of 2,925, 33.1%,
95% CI 31.4% to 34.8%) had used a self test, including
pregnancy tests (19%) and blood pressure monitors
(9.4%), and 287 people reported having used more than
one test (Table 2). Tests for diabetes had been used by
7.7% of respondents, fertility tests by 2.4% and urinary
infection tests by 2.3%. All other tests were used by less
than 2% of respondents.
Thirty five people (1.2%, 95% CI = 0.83% to 1.66%)
reported having used a cancer related self test kit: 8 had
used a faecal occult blood test (FOB) (0.3%), 13 had used
a test for haematuria (0.4%), and 16 had used a PSA test
(0.5% or 1.1% of males). Two people had used two cancer
related tests: one person had used PSA and FOB kits, and
the other had used FOB and haematuria kits. Cancer
related self-tests were used by 3.6% (35 of 969) of those
who had ever used a self-test, but a further 36% (1,055 of
2,925) of respondents who had never used a cancer-
related self-test reported that they would consider using
one in the future. Crude and standardized rates by test,
age and deprivation quartile are reported in Table 3; the
highest rate of cancer-related self-testing was observed for
PSA testing, rates substantially increasing with increasing
age.
The mean age of responders who had used a cancer related
test was 59 years (range 30 to 87); 60% (n = 21 of the 35
cancer self-test users) were male; 89% (n = 31) were white;
14% (n = 5) were smokers; 83% (n = 29) reported their
health to be good or fairly good; 40% (n = 14) were in
paid employment and 46% (n = 16) were retired; and
14% (n = 5) had a university degree. Previous use of a PSA
self-test was associated with increasing age (χ2 = 6.43, df =
1, p = 0.01) and white ethnic group (χ2 = 6.68, df = 1, p <
0.01). No significant associations were observed for hae-
maturia or colorectal cancer although the numbers avail-
able for analysis were very small. Characteristics of cancer-
related (i.e. PSA, haematuria and bowel) self-test users
and non users are compared in Table 1: no statistically sig-
nificant differences were observed between the two
groups.
Logistic regression analyses indicated that the predictors
of PSA test kit use were male gender (p < 0.01), white eth-
nicity (p < 0.01) older age (p < 0.01) and IMD quartile (p
< 0.05); there was a lower usage in subjects from IMD
quartile 3 (relatively deprived). For the haematuria test
kit, looking after the home/family employment and IMD
quartile 3 were both significant predictors of usage (p <
0.01 and p < 0.05 respectively). For use of a bowel cancer
test there were insufficient users to make any significant
conclusions although when usage was amalgamated with
that for the haematuria test kit, looking after home/family
again proved a significant factor (p < 0.05).
Future use of a PSA self test kit was associated with, male
gender (p < 0.001), younger age (p < 0.001) and IMD
quartile (p < 0.05), with men resident in IMD quartiles 1
and 2 (less deprived) being more likely to report possible
Table 2: Reported use, and potential future use, of any self-tests
Used Would Use
Test kit n % n %
Allergy 43 1.5 1137 38.9
Cholesterol 56 1.9 1453 49.7
Chlamydia 4 0.1 504 17.2
Diabetes 225 7.7 1371 46.9
Fertility 69 2.4 496 17.0
Helicobacter pylori 28 1.0 789 27.0
Hepatitis 3 0.1 644 22.0
High blood pressure 276 9.4 1469 50.2
HIV/AIDS 2 0.1 456 15.6
Menopause 16 0.5 537 18.4
Pregnancy 555 19.0 591 20.2
Thyroid 16 0.5 753 25.7
Urinary infection 67 2.3 1027 35.1
Vaginal infection 13 0.4 612 20.9
Other 5 0.2 41 1.4
All non-cancer 1378 11880
Reported use, and potential future use, of cancer related self-tests
Bowel Cancer 8 0.3 844 28.9
Haematuria 13 0.4 690 23.6
PSA 16 0.5 639 21.8
All cancer related *37 2173
*37 tests used by 35 peopleBMC Cancer 2008, 8:102 http://www.biomedcentral.com/1471-2407/8/102
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future use. Future use of a haematuria test was associated
with male gender (p < 0.05) and younger age (p < 0.001).
For a bowel cancer self test, again future use was associ-
ated with male gender (p < 0.05), younger age (p < 0.001),
and being in IMD quartiles 1 and 2 (p < 0.001)
Discussion and Conclusion
This postal population survey found that around one in
100 of the population have used a self test for cancer and
about a third of the population have used a self test for a
condition other than cancer, with pregnancy tests being
the most commonly used form of self-test. The two most
commonly used cancer self-tests were for PSA and haema-
turia, even though neither PSA testing nor testing for hae-
maturia are recommended screening procedures for
cancer in the UK.
More than a third of the population (36%) report that
they would consider using a cancer related self-test in the
future, but it is not anticipated that all those who may
consider future use would necessarily do so; actions being
likely to be prompted by the onset of symptoms, experi-
ences (e.g. diagnoses of cancer in friends or relatives) and
the perceived acceptability of cancer self-testing. Similarly,
if a wider range of self tests become available and their use
was more widely promoted and accepted, it is possible
that some of those who would not currently consider self
testing may subsequently do so.
Self-testing is marketed as a valuable way of alerting peo-
ple to serious health problems so that they can seek med-
ical help [29]. The only previous UK surveys addressing
the issue of self-testing report that 18% and 25% of peo-
ple would, respectively, prefer self-testing to testing by a
doctor and a pharmacist [30], and that 32% of people had
bought a self-test kit (although this did include pregnancy
tests) [31], similar to our results. Increased availability
and utilisation of self-testing may have public health
implications, particularly relating to the delivery of
national screening programmes [32]. Although other
work is now ongoing [33], this is the first study to report
the prevalence of self-testing for cancer.
This study had a response rate of 54%, and it is possible
that selection bias may have occurred so that responders
were different from the rest of the population in terms of
the frequency with which they have used self-tests. Com-
parison of the study population as a whole with census
data for the West Midlands suggests that respondents were
older (mean age: census 42, study 54) and more likely to
be female (census 51%, study 55%) but that the study
population included similar proportions of people
describing themselves as having white ethnicity (census
91%, study 92%). Standardised rates were calculated to
allow for the effect of response bias.
It is possible that respondents may have misinterpreted
the question about self-test use and may have included
the use of home monitoring, as opposed to self-diagnosis.
However this is unlikely to have affected the estimate of
cancer related test use, as such tests are not used for self-
monitoring. Conversely, it is possible that some respond-
ents perceived self-testing to be an unacceptable activity
and social desirability bias may have resulted in the
reported rate of use underestimating the true rate. We
have no information at present to determine the accuracy
of the responses to the survey. However, an ongoing
multi-method study [33] is considering respondent's
understanding of the definition of self-testing and the fac-
tors associated with use; this work will provide further
information relating to these potential biases.
We have demonstrated that 1% of the adult population
reported having used a cancer-related self-test kit and that
more than a third of the adult population reported that
they would consider using such a test in the future. Cancer
related self-testing may develop to include tests for the
early diagnosis of cancers at more sites, the genetic deter-
minants of disease [21] and drug effectiveness [22]. Self-
tests for cancer could alter perceptions of risk and health
behaviour, cause psychological morbidity, could poten-
tially be misused (e.g. if testing became a precedent to
employment) and could have a significant impact on the
demand for healthcare.
Table 3: Prevalence rates per 1,000 population – Crude and standardised to England
Crude rate Standardised rate Standardised rate Standardised rate
Test Kit Female 
(1617)
Male 
(1308)
All 
(95% CI)
Female 
(1617)
Male 
(1308)
Age <40 
(747)
Age 40 – 59 
(1066)
Age 60 + 
(1112)
IMD1 Q1 
(433)
IMD Q2 
(566)
IMD Q3 
(1230)
IMD Q4 
(693)
Bowel Cancer (n = 8) 3.1 2.3 2.7 (1.2, 5.4) 3.4 1.9 1.9 1.39 5.3 4.6 3.0 1.7 1.3
Haematuria (n = 13) 5.6 3.1 4.4 (2.4, 7.6) 3.9 3.0 4.8 2.8 2.3 0 1.3 8.8 3.8
PSA (n = 16) 0.6 11.5 5.5 (3.1, 8.9) 1.1 9.3 1.0 6.3 9.4 5.3 6.3 2.8 5.7
Any cancer self-test 
(n = 35)
8.7 16.06 12.0 (8.3, 16.6) 8.1 13.5 7.7 10.5 15.4 9.8 9.4 12.8 10.8
1IMD = Index of Multiple Deprivation, 2004BMC Cancer 2008, 8:102 http://www.biomedcentral.com/1471-2407/8/102
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